ROADMAP PARTNERS

ACADEMIA

UNIVERSITY OF OXFORD

THE UNIVERSITY of EDINBURGH

AARHUS UNIVERSITY

Maastricht University

LSE THE LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE
PSSRU
Personal Social Services Research Unit

rijksuniversiteit groningen

KØBENHAVNS UNIVERSITET

IDIAP Jordi Gol

LUMC Leids Universitair Medisch Centrum

GÖTEBORG UNIVERSITY

Erasmus MC
University Medical Center Rotterdam

EFPIA

NOVARTIS

AC Immune

Biogen.

Roche

Lilly

GE

Lundbeck

Janssen
PHARMACEUTICAL COMPANIES OF Johnson-Johnson

Takeda

REGULATORY AGENCIES

cBG MEB

SMEs

SYNAPSE
RESEARCH MANAGEMENT PARTNERS

PATIENT ORGANISATION

Alzheimer Europe

NICE National Institute for Health and Care Excellence

IXICO

ROADMAP
Real world Outcomes across the AD spectrum for better care

In the context of demographic change, Europe is facing an acute healthcare challenge. In no area is this more apparent than in Alzheimer's disease (AD) and dementia. **AD** and related dementias affect nearly **50 million** individuals worldwide with **prevalence** projected to **double** over the **next twenty years.**

So far there is no cure for AD and challenges in the evaluation of early disease interventions within the current assessment systems have not changed. Consequently, the precision medicine approach to health funding requires new models that encompass all the available evidence for the identification of best suited treatments for different groups within the AD continuum.

100M

50M

2017

2037

Visit our website www.roadmap-alzheimer.org

Follow us on Twitter @IMI2_ROADMAP

efpia

innovative medicines initiative

efpia

innovative medicines initiative

WHAT IS ROADMAP?

The **R**eal world **O**utcomes across the **A**lzheimer's **D**isease (AD) spectrum for better care: **M**ulti-modal data **A**ccess **P**latform (ROADMAP) project is a public private consortium with **25 partners** from Europe, coordinated by the University of Oxford and Novartis.

ROADMAP brings together leading institutions and companies with an interest in improving the situation of people with AD. Therefore, ROADMAPs goal is to establish a sustainable platform for real world evidence (RWE) data to better inform consensus and decisions. The project will deliver guiding principles and recommendations on incorporating RWE in healthcare systems.

In order to achieve this **ROADMAP** will use and analyse data of subjects from:

75 national databases and **clinical registries**	n ≈ 80M
More than **40 cohorts**	n ≈ 2M
Several studies using **wearables** and **smart devices**	n ≈ 100K
5 dementia relevant trials	n ≈ 100K

ROADMAP **welcomes additional database providers, interested universities, institutions as well as companies** to further **expand** its Europe-wide network towards a potential onboarding for a Phase 2

Contact us at info@roadmap-alzheimer.org

ROADMAP's OBJECTIVES

- Define and catalogue scales and consensus-based methodologies for identifying AD outcomes from routinely collected data.

- Identify and pool AD-related RWE data and establish solution options for how to combine different RWE sources with RCT data supporting pharmacoeconomic evaluation.

- Develop and validate a core disease progression model combining diverse datasets to facilitate analysis of disease trajectories and effect of interventions on disease trajectories.

- Develop a proof of concept AD cost-effectiveness and budget impact model for HTA agencies, regulators, service providers, industry, payers and carers.

- Develop guiding principles and recommendations from HTA/payers/regulators for the development and incorporation of RWE into clinical and market access development plans for AD.

- Develop and implement a communication strategy focusing on the needs of patients and professionals.

- Develop an Ethical, Legal, and Social Implications (ELSI) framework with extensive patient involvement for the development and application of RWE in AD.

- Develop a full plan for phase 2 of the ROADMAP initiative that addresses identified gaps and pitfalls, and exploits promising solutions to their full potential for development of a European RWE platform in AD.